Piper Jaffray Companies restated their hold rating on shares of Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) in a research note published on Friday. They currently have a $14.00 price target on the software maker’s stock.

Several other equities research analysts have also recently weighed in on MDRX. Bank of America Corporation began coverage on Allscripts Healthcare Solutions in a report on Monday, May 15th. They set a neutral rating and a $14.00 target price for the company. BidaskClub upgraded Allscripts Healthcare Solutions from a strong sell rating to a sell rating in a report on Tuesday, June 13th. Wells Fargo & Company upgraded Allscripts Healthcare Solutions from a market perform rating to an outperform rating in a report on Monday, March 27th. Maxim Group restated a buy rating and set a $16.00 target price on shares of Allscripts Healthcare Solutions in a report on Friday, May 5th. Finally, Cantor Fitzgerald restated a neutral rating and set a $13.00 target price on shares of Allscripts Healthcare Solutions in a report on Monday, May 15th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and ten have assigned a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $14.74.

Allscripts Healthcare Solutions (MDRX) opened at 12.19 on Friday. The firm’s market capitalization is $2.21 billion. The company has a 50 day moving average price of $12.41 and a 200-day moving average price of $12.07. Allscripts Healthcare Solutions has a 1-year low of $9.80 and a 1-year high of $15.17.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last issued its earnings results on Thursday, May 4th. The software maker reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.01. The company had revenue of $415 million during the quarter, compared to analysts’ expectations of $415.20 million. Allscripts Healthcare Solutions had a positive return on equity of 5.75% and a negative net margin of 2.93%. Allscripts Healthcare Solutions’s quarterly revenue was up 20.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.13 EPS. On average, analysts forecast that Allscripts Healthcare Solutions will post $0.62 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/allscripts-healthcare-solutions-inc-nasdaqmdrx-given-hold-rating-at-piper-jaffray-companies/1458600.html.

In other news, President Richard J. Poulton sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $12.06, for a total value of $301,500.00. Following the completion of the transaction, the president now owns 412,488 shares in the company, valued at approximately $4,974,605.28. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.75% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Allscripts Healthcare Solutions by 3.7% in the first quarter. Vanguard Group Inc. now owns 14,642,919 shares of the software maker’s stock worth $185,672,000 after buying an additional 519,798 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Allscripts Healthcare Solutions by 9.4% in the first quarter. Dimensional Fund Advisors LP now owns 7,227,789 shares of the software maker’s stock worth $91,648,000 after buying an additional 621,620 shares during the last quarter. Fiduciary Management Inc. WI boosted its position in Allscripts Healthcare Solutions by 28.5% in the first quarter. Fiduciary Management Inc. WI now owns 6,045,110 shares of the software maker’s stock worth $76,652,000 after buying an additional 1,341,870 shares during the last quarter. First Trust Advisors LP boosted its position in Allscripts Healthcare Solutions by 48.0% in the first quarter. First Trust Advisors LP now owns 5,855,944 shares of the software maker’s stock worth $74,253,000 after buying an additional 1,898,007 shares during the last quarter. Finally, Boston Partners boosted its position in Allscripts Healthcare Solutions by 12.0% in the first quarter. Boston Partners now owns 4,648,327 shares of the software maker’s stock worth $58,941,000 after buying an additional 498,267 shares during the last quarter.

About Allscripts Healthcare Solutions

Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.

Analyst Recommendations for Allscripts Healthcare Solutions (NASDAQ:MDRX)

Receive News & Ratings for Allscripts Healthcare Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.